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Abstract Extracellular signal-regulated kinase (ERK) activa-
tion pathways have been well characterized in a number of cell
types but very few data are available for platelets. The throm-
bin-induced signaling pathway leading to ERK2 activation in
platelets is largely uncharacterized. In this study, we investi-
gated the kinases involved in thrombin-induced ERK2 activation
in conditions of maximal ERK2 activation. We found that
thrombin-induced mitogen-activated protein kinase/ERK kinase
(MEK)1/2 activation was necessary for ERK2 phosphorylation.
We obtained strong evidence that conventional protein kinase
Cs (PKCs) and calcium are involved in thrombin-induced ERK2
activation. First, ERK2 and MEK1/2 phosphorylation was to-
tally inhibited by low concentrations (1 WM) of RO318425, a
speci¢c inhibitor of conventional PKCs. Second, Ca2+, from
either intracellular pools or the extracellular medium, was nec-
essary for ERK2 activation and conventional PKC activation,
excluding the involvement of a new class of calcium-insensitive
PKCs. Third, LY294002 and wortmannin had no signi¢cant
e¡ect on ERK2 activation, even at concentrations that inhibit
phosphatidylinositol (PI)3-kinase (5 WM to 25 WM and 50 nM,
respectively). This suggests that PI3-kinase was not necessary
for ERK2 activation and therefore, that PI3-kinase-dependent
atypical PKCs were not involved. Surprisingly, in contrast to
proliferative cells, we found that the serine/threonine kinases
Raf-1 and B-Raf were not an intermediate kinase between con-
ventional PKCs and MEK1/2. After immunoprecipitation of
Raf-1 and B-Raf, the basal glutathione S-transferase^MEK1
phosphorylation observed in resting platelets was not upregu-
lated by thrombin and was still observed in the absence of
anti-Raf-1 or anti-B-Raf antibodies. In these conditions, the in
vitro cascade kinase assay did not detect any MEK activity.
Thus in platelets, thrombin-induced ERK2 activation is acti-
vated by conventional PKCs independently of Raf-1 and
B-Raf activation.
; 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitogen-activated protein kinases (MAPKs) are a family of
serine/threonine kinases [1] divided into three subgroups:
extracellular signal-regulated kinases (ERKs), c-Jun N-termi-
nal kinases (JNKs), and p38 MAPK (p38MAPK). The signaling
pathways and the role of MAPKs, especially ERKs, have
been extensively investigated in proliferative cells [2]. Brie£y,
ERKs may be activated by growth factors and hormones with
tyrosine kinase receptors [3], G protein-coupled receptors [4]
and by integrins [5]. The signaling pathway ¢rst induces acti-
vation of the small G protein Ras by conversion from an
GDP-bound to a GTP-bound state [6]. This is followed by
interaction between Ras and the serine/threonine kinase
Raf-1. Raf-1 phosphorylation leads to activation of the dual
tyrosine/threonine-speci¢c MAPK/ERK kinase (MEK)1
and MEK2 [7], which in turn phosphorylate and activate
ERK1 and ERK2 at threonine and tyrosine residues [8].
Active ERKs elicit many of the e¡ects of extracellular sig-
nals, through the regulation and phosphorylation of many
substrates, including phospholipase A2 [9] and p90rsk
[10] and nuclear proteins, such as p62TCF or Elk-1 [11],
leading to proliferation [12], di¡erentiation [13] and adhesion
[14].
In contrast, the signal transduction mechanisms leading to
the activation of MAPKs in platelets are largely uncharacter-
ized. ERK1, ERK2 and p38MAPK have been detected in plate-
lets. [15,16]. Recently, we found that JNK1 is also present in
human platelets and activated after thrombin induction [17].
The members of all three families (ERK2, p38MAPK and
JNK1) are activated by physiologic agonists including throm-
bin [18] and collagen [19]. ERK2 activation is mediated by the
dual-speci¢city kinase MEK1/2 [20] and seems to involve a
protein kinase C (PKC)-dependent pathway [21]. H-Ras [22]
and Raf-1 [23] have been shown to be present in platelets,
but the relationships between the upstream kinases involved
in the activation of ERK2 are unknown. Finally, we have
found that in human platelets, the activation of ERK2 and
JNK1 by thrombin is negatively regulated by KIIbL3 engage-
ment in aggregation [24,17]. These reports were the ¢rst to
show the downregulation of MAPKs (ERK2 and JNK1) by
an integrin.
In this study, we investigated the putative kinases involved
in thrombin-induced ERK2 activation. We found that throm-
bin-induced ERK2 activation was dependent on both cal-
cium and conventional PKCs but independent of Raf-1 and
B-Raf.
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2. Materials and methods
2.1. Reagents
Bovine K-thrombin, the synthetic peptide Arg-Gly-Asp-Ser
(RGDS), myelin basic protein (MBP), leupeptin and aprotinin
were purchased from Sigma (St. Louis, MO, USA). RO318425,
GF109203X, wortmannin and LY294002 were purchased from Cal-
biochem (Meudon, France). BAPTA-AM and PD98059 were from
Biomol (Plymouth Meeting, PA, USA). Rabbit polyclonal antibodies
raised against the C-terminal peptides of ERK1/2 (C-14), Raf-1 (C-12)
and B-Raf (C-19) and monoclonal antibody directed against PKC(s)
(MC5) were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Rabbit polyclonal antibody directed against the phosphor-
ylated forms of ERKs (ERKs-P) was obtained from Promega (Mad-
ison, WI, USA. Rabbit polyclonal antibodies directed against the
phosphorylated form of MEK1/2 (MEK1/2-P) and Akt (Akt-P)
were purchased from New England Biolabs (Beverly, MA, USA).
Inactive GST^MEK1 was obtained from Upstate Biotechnology
(Lake Placid, NY, USA). Donkey anti-rabbit horseradish peroxi-
dase-conjugated IgG was obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA) and [Q-32P]ATP (167 TBq/
mmol) from ICN (Irvine, CA, USA). A Raf immunoprecipitation
kinase cascade assay kit was purchased from Upstate Biotechnology
(Lake Placid, NY, USA). Thrombopoietin (TPO) mimetic peptide was
a generous gift from Dr. A. Dubart (Paris, France).
2.2. Platelet preparation and aggregation
Venous blood was collected from healthy donors free of medication
for at least 2 weeks. Platelet-rich plasma was obtained by centrifuga-
tion of whole blood at 120Ug for 15 min at 21‡C, and platelets were
isolated by di¡erential centrifugation, in citrate bu¡er, pH 6, contain-
ing 1034 mM prostaglandin E1, 140 mM NaCl, 5 mM KCl, 12 mM
trisodium citrate, 10 mM glucose, and 12.5 mM sucrose, and then in
the same bu¡er but without prostaglandin E1. The platelet pellet was
resuspended in 10 mM HEPES, pH 7.4, 140 mM NaCl, 3 mM KCl,
0.5 mM MgCl2, 5 mM NaHCO3, and 10 mM glucose. Cell concen-
tration was adjusted to 5U108/ml. Platelets (0.4 ml) were preincu-
bated at 37‡C, without stirring, for various times, with various mol-
ecules. Platelet aggregation was then initiated by adding bovine
thrombin (1 NIH U/ml), with constant stirring (1200 rpm) in an
aggregometer cuvette (Chronolog dual beam aggregometer). Aggrega-
tion was measured and expressed as a percent change in the trans-
mission of light, with the blank sample (bu¡er without platelets) de-
¢ned as 100%.
2.3. Immunoblotting
Samples were subjected to immunoblotting as described previously
[24]. Brie£y, platelet lysates were obtained by adding sodium dodecyl
sulfate (SDS) denaturing bu¡er and heating the samples at 95‡C for
5 min. Proteins were subjected to 12% SDS^polyacrylamide gel elec-
trophoresis (PAGE) and transferred to nitrocellulose ¢lters by semi-
dry transfer (Enprotech, Natick, MA, USA). Filters were then incu-
bated for 1 h at room temperature with the primary polyclonal anti-
body: anti-ERKs (1:20 000), anti-ERKs-P (1:20 000), anti-MEK1/2-P
(1:500), anti-Akt-P (1:1000), anti-Raf-1 (1:1000) and anti-B-Raf
(1:1000). Membranes were washed ¢ve times with phosphate-bu¡ered
saline, without milk. They were then incubated with either horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:20 000 or 1:10 000) or
with peroxidase-conjugated rabbit anti-mouse IgG (1:10 000) for 45
min at room temperature. Immunoreactive bands were detected by
enhanced chemiluminescence (Pierce).
2.4. Raf kinase assay
Immunoprecipitation and in vitro kinase assay for Raf-1 and
B-Raf: platelet lysates were obtained by adding 40 Wl of lysis bu¡er
(10% Triton, 500 WM NaF, 100 mM L-glycerophosphate, pH 7.5).
Platelet lysates (800 Wl) were incubated overnight at 4‡C with the
polyclonal anti-Raf-1 antibody (2 Wg/sample) or anti-B-Raf (3 Wg/
sample) and then with protein-A or protein-G Sepharose beads for
2 h at 4‡C. Immunoprecipitates were washed three times in bu¡er A
(0.2% Triton, 10 mM Tris, pH 8, 150 mM NaCl, 2 mM EDTA, 40
mM L-glycerophosphate, 0.2 mM orthovanadate, 5 Wg/ml leupeptin,
10 Wg/ml aprotinin), once in bu¡er B (bu¡er A supplemented with 500
mM NaCl), once in bu¡er A, once in bu¡er C (10 mM Tris, 40 mM
L-glycerophosphate, 0.2 mM orthovanadate, 5 Wg/ml leupeptin, 10 Wg/
ml aprotinin, pH 7.2) and once in kinase bu¡er (20 mM HEPES, pH
7.2, 10 mM MgCl2, 10 mM MnCl2). The samples were then resus-
pended in 20 Wl of kinase bu¡er supplemented with inactive GST^
MEK1 (1 Wg) and with 10 WCi of [Q-32P]ATP and 1 WM of unlabeled
ATP. After 30 min at 30‡C, the reaction was stopped by adding
Laemmli bu¡er, and the samples were subjected to 10% SDS^
PAGE. The gel was then stained, dried and subjected to autoradiog-
raphy and phosphorylated GST^MEK was analyzed.
Culture and cell treatment of human megakaryoblastic UT7-Mpl
expressing the full-length murine TPO receptor Mpl was processed as
previously described [25].
Raf activity was measured according to the manufacturer’s instruc-
tions. Brie£y, after immunoprecipitation of Raf-1 or B-Raf, the in
vitro kinase cascade reaction was initiated by adding inactive GST^
MEK1 and inactive GST^ERK. MBP was added as a substrate with
[Q-32P]ATP. The reaction mixtures were spotted onto phosphocellulose
membranes. After several washings, the radioactivity of each spot,
corresponding to phosphorylated MBP (MBP-32P), was quanti¢ed.
3. Results
3.1. MEK1/2 activation is necessary for thrombin-induced
ERK2 activation
We have shown that platelet ERK2 is activated by
K-thrombin [24]. To identify the signaling pathway involved
in thrombin-induced ERK2 activation, we ¢rst investigated
the involvement of MEK1/2, the tyrosine/threonine kinase
directly responsible for ERK2 activation, in conditions of
maximal ERK2 activation. We used thrombin activation in
the presence of RGDS peptide, which completely blocks
KIIbL3 integrin engagement and as we have previously dem-
onstrated, upregulates ERK2 activity. We ¢rst compared the
kinetics of ERK2 and MEK1/2 activation with and without
PD98059, a speci¢c inhibitor of MEK1/2. Western blotting
was performed, using an antibody recognizing only the phos-
phorylated forms of ERK2 (ERK2-P), MEK1/2 (MEK1/2-P)
(Fig. 1A,B) or total ERK2 (Fig. 1C). The phosphorylation of
Fig. 1. E¡ect of PD98059 on the phosphorylation of ERK2 and
MEK1/2. Washed platelets were preincubated with stirring, for
1 min, with or without PD98059 (20 WM) and were then stimulated
with thrombin (1 NIH U/ml) in the presence of the RGDS peptide
(1 mM) for various times, with stirring. Platelet lysates were ana-
lyzed by SDS^PAGE followed by Western blotting using antibodies
recognizing ERK2-P (A), MEK1/2-P (B) and total ERK2 (C). Re-
sults are representative of four experiments.
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ERK2 and MEK1/2 was detected after 1 min of thrombin
stimulation and peaked at 3 min. Preincubation with
PD98059 (20 WM) for 1 min inhibited the activation of
ERK2 and MEK1/2 (Fig. 1A,B). These results con¢rm that
MEK1/2 activates ERK2 in human platelets.
3.2. Thrombin-induced ERK2 activation is dependent on
calcium and conventional PKCs
We next investigated whether PKCs, a serine/threonine ki-
nase, could activate MEK1/2 and consequently ERK2, as
previously demonstrated in other cell systems such as COS
cells [26], and in angiotensin II-induced vascular smooth
muscle cell activation [27]. Thrombin-induced ERK2 and
MEK1/2 activation was assessed in the presence and absence
of a selective inhibitor of PKC, RO318425, which is known to
inhibit conventional PKCs [28]. Platelets were incubated with
various concentrations of RO318425 (0^10 WM) for 2 min
with stirring. Activation, as assessed by Western blotting,
was inhibited by 90% for ERK2 and 100% for MEK1/2 by
1 WM of RO318425 (Fig. 2A). Consistent results were ob-
tained in kinetic studies in which the activation of ERK2
and MEK1/2 was blocked at all time points (Fig. 2B). Similar
results were also obtained with another speci¢c inhibitor of
PKCs, GF109203X (data not shown). To con¢rm the involve-
ment of PKCs, we investigated the e¡ect of phorbol myristate
acetate (PMA) on the activation of MEK1/2 and ERK2.
PMA (500 nM) induced the activation of MEK1/2 and
ERK2. Activation became detectable after 1^2 min, depend-
ing on the experiment and reached a maximum between 2 and
3 min (Fig. 2C). These results suggest that thrombin-induced
MEK1/2 activation and subsequent ERK2 activation, are
mediated by a conventional PKC-dependent pathway.
Conventional PKC isoenzymes are activated via a calcium-
dependent mechanism. We investigated the putative role of
calcium in the pathway of ERK2 activation induced by
thrombin. Platelets were resuspended in the presence or ab-
ERK2-P
MEK1/2-P
B
1 12 20 3 3 Time (min)
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RO-318425 (1 M)µ + + +
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Fig. 2. E¡ect of PKCs on the activation of MEK1/2 and ERK2. Washed platelets were preincubated without stirring for 10 min with various
concentrations of RO318425 (0.1, 1 and 10 WM) (A) or with 1 WM of RO318425 (B) in the presence or absence of RGDS peptide (1 mM).
They were then stimulated with thrombin (1 NIH U/ml) (A,B) with stirring for 2 min (A) or the times indicated (B) or with PMA (500 nM)
(C). The platelets were solubilized in SDS bu¡er and analyzed for ERK2 activation by SDS^PAGE followed by Western blotting, as described
in Fig. 1. Results are representative of ¢ve experiments.
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sence of calcium (1 mM) and stimulated by incubation with
thrombin (1 NIH U/ml) for 2 min (Fig. 3A). In these condi-
tions, the phosphorylation of ERK2 and MEK1/2 was max-
imal with calcium (1 mM) in platelet suspension bu¡er. Den-
sitometric analysis showed ¢ve times more ERK2
phosphorylation and three times more MEK1/2 phosphoryla-
tion in the presence of extracellular calcium than in the ab-
sence of calcium (Fig. 3A), suggesting that calcium in£ux may
be involved in thrombin-induced ERK2 activation. The phos-
phorylation of ERK2 and MEK1/2 was completely inhibited
if platelets were incubated in the absence of extracellular cal-
cium and with 0.2 mM BAPTA, a chelator of intracellular
calcium. Thus, the activation of MEK1/2 and ERK2 by
thrombin is dependent on intracellular calcium. These results
suggest a key role in the activation of MEK1/2 and ERK2 by
thrombin of cytosolic calcium originating from (1) the extra-
cellular medium and (2) the release of calcium from intracel-
lular stores. This is consistent with a central role for calcium-
dependent PKCs (the conventional class of PKCs) and seems
to exclude involvement of the new class of calcium-indepen-
dent PKC(s). We also investigated the role of the atypical
class of PKCs, such as PKCj, which is activated by the prod-
ucts of phosphatidylinositol (PI)3-kinase [29]. Wortmannin
(10^50 nM) and LY294002 (5^25 WM) were used to inhibit
PI3-kinase activity. Concentrations of wortmannin (50 nM)
and LY294002 (5^25 WM) that inhibited Akt phosphorylation
(Akt-P) had no e¡ect on thrombin-induced ERK2 activation
in the presence of RGDS peptide (Fig. 3B). Thus, PI3-kinase
has no e¡ect on ERK2 activation, suggesting that atypical
PKCs are not involved in thrombin-induced ERK2 activation.
Overall, these results are consistent with the mediation of
thrombin-induced ERK2 activation by conventional PKCs.
3.3. Raf-1 and B-Raf are not involved in thrombin-induced
ERK2 activation
We next assessed the involvement of the classical serine/
threonine kinase Raf-1, which has been reported to be acti-
vated by PKCs [30] and to activate MEK1/2 directly in pro-
liferative cells [31]. Raf-1 has been detected in platelets [23].
We therefore investigated whether it was activated by throm-
bin. After immunoprecipitation of Raf-1 followed by in vitro
phosphorylation of GST-MEK1, basal phosphorylation of
GST-MEK1, detected in resting platelets, was not increased
after thrombin induction in the presence of RGDS peptide,
conditions of maximal ERK2 activation (Fig. 4A). Moreover,
in the absence of Raf-1 antibody, a non-speci¢c phosphory-
lation of GST^MEK1 was still observed in resting platelets,
suggesting that the basal phosphorylation of GST^MEK1 was
independent of Raf-1 activity and that the observed phos-
phorylation occurs at sites that are not involved in MEK
activation by kinases other than Raf-1. In contrast, in smooth
muscle cells, used as a positive control, platelet-derived
growth factor (PDGF) induced an activation of Raf-1 com-
pared with quiescent cells. The apparent di¡erence in molec-
ular weight of the Raf-1 in platelets and that in smooth
muscle cells may be due to species di¡erences (humans versus
pigs) and/or di¡erent states of Raf-1 phosphorylation as pre-
viously described [32]. Moreover, Raf-1 activity was assessed
in the presence and absence of the PKC inhibitor RO318425
(10 WM), which inhibited thrombin-induced ERK2 phosphor-
ylation. Basal phosphorylation of GST^MEK was still ob-
served in the presence of RO318425 in resting platelets and
after 2 min of thrombin stimulation (Fig. 4B) whereas throm-
bin-induced ERK2 phosphorylation was totally inhibited
(data not shown). Finally, to investigate whether basal
MEK phosphorylation (Fig. 4A) masks phosphorylation on
sites leading to MEK activation, we performed a cascade as-
say to measure MEK activation. Thus, after immunoprecipi-
tation of Raf-1 a cascade assay was performed, in which
GST^MEK phosphorylated GST^ERK, which in turn phos-
phorylated a substrate such as MBP. In these conditions, a
basal phosphorylation of MBP-32P was observed in resting
platelets and after thrombin induction. This phosphorylation
BAPTA (0.2 mM)
+
+
+
+
ERK2-P
THROMBIN
MEK1/2-P
A
Akt-P
ERK2-P
ERK2
Wortmannin (nM) 10 20 50
Thrombin
B
Akt-P
ERK2-P
LY294002 ( M)µ 105 25
Thrombin
ERK2
ERK2-P
Ca  (1mM)++
Fig. 3. Role of conventional PKCs on the phosphorylation of
MEK1/2 and ERK2. A: E¡ect of Ca2þ. Washed platelets, with or
without calcium (1 mM) in the extracellular medium were preincu-
bated without stirring for 10 min in the presence or absence of
BAPTA (0.2 mM). They were then stimulated by thrombin (1 NIH
U/ml), with stirring for 2 min. Platelet lysates were obtained as pre-
viously described and analyzed by SDS^PAGE followed by Western
blotting using polyclonal antibodies recognizing MEK1/2-P, ERK2-
P or total ERK. Results are representative of ¢ve experiments.
B: E¡ect of wortmannin and LY294002. Washed platelets were pre-
incubated for 20 min without stirring with various concentrations of
LY294002 (5^25 WM) or wortmannin (10^50 nM) in the presence of
RGDS peptide (1 mM). They were then stimulated with thrombin
(1 NIH U/ml). Samples were solubilized in SDS bu¡er and sub-
jected to SDS^PAGE followed by Western blotting as described
previously. Results are representative of ¢ve experiments.
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reached the same level as in the negative control in the ab-
sence of anti-Raf1 (Fig. 4C). Thus, Raf-1 was unable to in-
duce MEK activity in resting platelets and after thrombin
induction. This strongly suggests that kinases other than
Raf-1 phosphorylate MEK on sites that are not involved in
MEK activation (Fig. 4A). In contrast, as a positive control,
Raf-1 activity was measured in megakaryoblastic UT7-Mpl
cell line stimulated with a TPO mimetic peptide. A 2.57-fold
increase of immunoprecipitated Raf-1 activity was observed
after 1 h of stimulation by TPO (10 nM).
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Fig. 4. Raf-1 activity in thrombin-stimulated platelets. Washed platelets were preincubated in the presence of the RGDS peptide (1 mM) and
then activated by thrombin (1 NIH U/ml) (A, C) for various times or (B) with 10 WM of RO318425. Samples were solubilized in Triton bu¡er
and then immunoprecipitated with an antibody directed against Raf-1. A,B: The exogenous substrate, GST^MEK1, was phosphorylated after
the immunoprecipitation of Raf-1. C: In vitro kinase assay of MEK activation: Raf-1 was immunoprecipitated and then a cascade assay was
carried out in which GST^MEK phosphorylated GST^ERK, which in turn phosphorylated MBP. Smooth muscle cells stimulated with 10 ng/
ml of PDGF (5 min) and UT7-Mpl stimulated with 10 nM TPO mimetic peptide (1 h) were used as a positive control. Results are representa-
tive of three experiments.
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All together, these data show that Raf-1 activity is not
required for ERK2 activation.
We also tested another isoform of Raf, B-Raf, which is
present in hematopoietic cells [33]. B-Raf was present in plate-
let lysate (data not shown). After immunoprecipitation of
B-Raf followed by in vitro phosphorylation of GST^MEK1,
a basal level of activated B-Raf was detected in resting plate-
lets which was not upregulated by thrombin (Fig. 5A). More-
over, in the presence of the PKC inhibitor RO318427 (10
WM), the basal phosphorylation of GST^MEK was a¡ected
but still detectable (Fig. 5B). Like for Raf-1, we performed a
cascade assay to measure MEK activation rather than phos-
phorylation. After immunoprecipitation of B-Raf, a cascade
assay was performed with ATP, GST^MEK, GST^ERK and
MBP. In these conditions, a basal phosphorylation of MBP-
32P was observed in resting platelets and after thrombin in-
duction. This phosphorylation reached the level observed in
the negative control in the absence of anti-B-Raf (Fig. 5C).
B-Raf activity was still processed in TPO stimulated UT7-Mpl
cell line as a positive control. We observed a 2.75-fold in-
crease of the kinase activity after 4 h of stimulation by TPO
(10 nM).
These results show that B-Raf is not involved in thrombin-
induced MEK activation and suggest that kinases other than
B-Raf phosphorylate MEK on sites (Fig. 5A) that are not
involved in MEK activation. All these results suggest that
B-Raf and Raf-1 are not involved in MEK/ERK activation
after thrombin stimulation.
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Fig. 5. B-Raf activity in thrombin-stimulated platelets. Washed platelets were preincubated in the presence of the RGDS peptide (1 mM) and
then activated by thrombin (1 NIH U/ml) (A,C) for various times or (B) with 10 WM of RO318425. Samples were solubilized in Triton bu¡er
and then immunoprecipitated with an antibody directed against B-Raf. A,B: The exogenous substrate, GST^MEK1, was phosphorylated after
the immunoprecipitation of B-Raf. C: In vitro kinase assay of MEK activation: B-Raf was immunoprecipitated and then a cascade assay was
carried out in which GST^MEK phosphorylated GST^ERK, which in turn phosphorylated MBP. UT7-Mpl were stimulated with 10 nM TPO
mimetic peptide (4 h) as a positive control. Results are representative of three experiments.
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4. Discussion
The MAPK signaling pathway induced by various agonists
including thrombin [18], collagen [19] and PMA [21] is largely
uncharacterized. Recently, MEK1/2 [20] and PKC [21] have
been shown to be involved in ERK2 activation in human
platelets, but the link between receptor and kinases remains
to be established. In this study, we investigated thrombin-in-
duced ERK2 activation and the putative kinases involved in
this pathway.
We found that the inhibition of MEK1/2 by PD98059, in-
hibited the phosphorylation of both MEK1/2 and ERK2,
consistent with previous results [20] showing that MEK1/2 is
directly involved in ERK2 activation. We next investigated
the possible involvement of a family of serine/threonine ki-
nases, the PKCs. We showed, using various approaches,
that calcium and conventional PKCs were involved. ERK2
activation was totally inhibited by a conventional PKC inhib-
itor, and calcium was necessary for the activation of both
ERK2 and conventional PKCs, excluding the involvement
of the new class of calcium-insensitive PKCs. PI3-kinase,
which is necessary for the activation of atypical PKCs, had
no e¡ect on ERK2 activation, suggesting that PI3-kinase ac-
tivation was not necessary for ERK2 activation and that atyp-
ical PKCs were not involved. Moreover, PMA, which directly
activates PKCs, induced ERK2 activation, but to a lesser
extent than thrombin. It is possible that the level of calcium
mobilization necessary for ERK2 activation was lower after
PMA induction than after thrombin induction. It is also pos-
sible that the conventional PKCs induced by thrombin and
PMA are di¡erent or that the PKCs involved in ERK2 acti-
vation are necessary but not su⁄cient for maximal ERK2
activation. Finally, PMA may induce a speci¢c phosphatase
that has a direct e¡ect on ERK2 activation. Our studies have
shown that both calcium mobilization and conventional PKC
activation are essential for ERK2 activation. Conventional
PKCs were required for MEK1/2 activation, but it was un-
clear whether the mechanism was direct or indirect. We have
investigated some possible intermediate components in ERK2
activation. MEK1/2 is activated by the serine/threonine kinase
Raf-1 in proliferative cells [30]. The role of Raf-1 activation in
platelets, in which it has been detected [23] is unclear. TPO
may induce Raf-1 activation in platelets without subsequently
inducing the activation of MEK1/2 or ERK2 [23]. In our
conditions, no activation of Raf-1 was observed after throm-
bin stimulation. Basal phosphorylated GST^MEK1 was still
observed after thrombin induction when Raf-1 was not im-
munoprecipitated, suggesting that the phosphorylation of
GST^MEK1 is independent of Raf-1 activity and that kinases
other than Raf-1 induce MEK phosphorylation on sites that
are not involved in its activation. To strengthen our results,
MEK activation was measured after immunoprecipitation of
Raf-1. In these conditions, basal phosphorylation of MBP
was observed in resting platelets and after thrombin induction
in the presence or absence of the anti-Raf-1 antibody. These
results con¢rm that MEK is not active in all conditions and
suggest that basal Raf-1-independent GST^MEK phosphory-
lation occurs on sites that are not involved in MEK activa-
tion. Moreover, GST^MEK1 phosphorylation was still ob-
served in the presence of conventional PKC inhibitors in
resting platelets and after thrombin stimulation even though
thrombin-induced ERK2 phosphorylation was totally inhib-
ited. Finally, Raf-1 did not coimmunoprecipitate with MEK1/
2 (data not shown). Taken together, our results strongly sug-
gest that Raf-1 activity is not required for ERK2 activation.
The other isoform of Raf, B-Raf, was detected in platelets.
The basal GST^MEK phosphorylation and activity detected
in resting platelets and after thrombin stimulation after the
immunoprecipitation of B-Raf, were still observed when
B-Raf was not immunoprecipitated. Thus, B-Raf was not re-
quired for ERK2 activation and, like Raf-1, MEK phosphor-
ylation occurs at sites that are not involved in MEK activa-
tion, probably by contaminating kinases in the precipitate.
The third isoform of Raf, A-Raf, has not been found in
platelets. In proliferative cells, A-Raf is weakly activated by
oncogenic ras and in proliferative cells it is strongly activated
by src [34]. In platelets, we con¢rmed the previous ¢nding [35]
that src is not involved in thrombin-induced ERK activation
(results not shown) using a src kinase inhibitor (PP1). The
activation of Ras is not coupled to ERK activation in human
platelets [35]. These results suggest that A-Raf is not involved
in platelet ERK2 activation. Taken together, our results
strongly suggest that thrombin-induced ERK activation does
not involve the classical Raf-MEK1/2-ERK cascade but in-
stead depends on calcium and the conventional PKCs^MEK1/
2^ERK pathway.
Finally, phospholipase CL linked to Gq protein induced the
formation of IP3 and diacylglycerol necessary for calcium
release and PKC activation in platelets, which suggests that
phospholipase CL is involved in upstream ERK pathway.
Our observations are consistent with recent data showing
that both calcium and PKC activity contribute to the P2Y-
induced activation of ERK independently of Raf-1 [36].
Moreover, activation of Ras and p42^p44 MAPKs by throm-
bin has been described to be uncoupled in platelets [35] sug-
gesting that classical cascade Ras^Raf^MEK^ERK does not
occur. Finally, in PC12 cells, calcium in£ux is necessary for
ERK activation independently of A-Raf, B-Raf, and C-Raf
activities [37]. Our data suggest that a MEK kinase other than
Raf-1 may be activated by conventional PKCs. Alternatively,
PKCs may act directly on MEK1/2. PKCs have been reported
to activate MEK1/2 in COS cells both in vitro and in vivo
[26]. PKCj may act independently of Raf activation to trigger
MEK and p42MAPK [38]. PKCj is activated by the products of
PI3-kinase and the inhibition of PI3-kinase has no e¡ect on
ERK2 activation, suggesting that this class of PKCs is not
involved in MEK1/2 activation.
In conclusion, we report that thrombin-induced activation
of ERK2 in human platelets is not dependent on Raf-1 or
B-Raf activation but instead dependent on calcium and the
conventional PKCs pathway.
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